Opinion: In mifepristone case, the Supreme Court must affirm the FDA’s authority. Medical innovation is at risk
On Wednesday, the Supreme Court announced it will soon weigh in on a case that challenges how the Food and Drug Administration regulates mifepristone, a drug it approved almost 25 years ago that is used to terminate pregnancy.
The case, the Alliance for Hippocratic Medicine v. FDA, is disguised as a dispute over safety. In reality, it’s about whether the courts will go along with overturning, for political reasons, the authority of the FDA as the scientific arbiter of approval of new drugs and restrictions on their distribution.
